Ascendis Pharma A/S

corporate_fare Company Profile

Ascendis Pharma A/S

ASND·NASDAQ·Life Sciences·CIK 0001612042

Ascendis Pharma A/S is a biopharmaceutical company that develops TransCon-based therapies for medical needs in Europe, the United States, and internationally. The company offers SKYTROFA, which treats pediatric patients with growth hormone deficiency. It also provides YORVIPATH, a once-daily subcutaneous injection for adults with chronic hypoparathyroidism. Ascendis Pharma A/S is developing a pipeline of three independent endocrinology rare disease product candidates that are in clinical development. Additionally, the company focuses on advancing oncology therapeutic candidates. It was incorporated in 2006 and is based in Hellerup, Denmark.

Ascendis Pharma A/S (NASDAQ:ASND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for ASND at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

Ascendis Pharma Reports Positive Phase 2 Results for TransCon hGH in Turner Syndrome (2026-03-17)
Ascendis Pharma's Once-Weekly Growth Hormone Matches Daily Therapy in Turner Syndrome Trial (2026-03-17)
Ascendis Pharma Reports Strong Two-Year Data for Approved Achondroplasia Drug TransCon CNP (2026-03-16)
Pivotal Trial Shows TransCon CNP's Durable Two-Year Benefits in Achondroplasia (2026-03-16)
CEO Files Intent to Sell $22.7M in Shares from Expiring Warrants (2026-03-05)

Financial Snapshot

Fiscal year ended December 31, 2025

Revenue

€720.13M EUR

Net Income

-€228.03M EUR

Diluted EPS

-€3.76 EUR

Op. Cash Flow

€53.9M EUR

Gross Profit

€625.22M EUR

Operating Income

-€136.27M EUR

Cash & Equivalents

€616.04M EUR

Total Debt

€385.25M EUR

Debt / Equity

-2.37×

Net Margin

-31.7%

Shares Outstanding

61.98M sh

Source: 20-F · filed 2026-02-11 · accession 0001193125-26-046590

Insider Transactions

ASND files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

show_chartPrice Chart

Loading chart...

feed ASND - Filings & News (Page 2)

Filing Type

Date Range

ASND

Mar 17, 2026, 4:05 PM EDT

Filing Type: 6-K

Importance Score:

Ascendis Pharma Reports Positive Phase 2 Results for TransCon hGH in Turner Syndrome

Price at Filing: $228.06

Real-time Price: $263.52

Change: +$35.45 (+16%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Mar 17, 2026, 8:30 AM EDT

Source: GlobeNewswire

Importance Score:

Ascendis Pharma's Once-Weekly Growth Hormone Matches Daily Therapy in Turner Syndrome Trial

Price at Filing: $231.12

Real-time Price: $263.52

Change: +$32.39 (+14%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Mar 16, 2026, 4:05 PM EDT

Filing Type: 6-K

Importance Score:

Ascendis Pharma Reports Strong Two-Year Data for Approved Achondroplasia Drug TransCon CNP

Price at Filing: $231.03

Real-time Price: $263.52

Change: +$32.49 (+14%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Mar 16, 2026, 8:00 AM EDT

Source: GlobeNewswire

Importance Score:

Pivotal Trial Shows TransCon CNP's Durable Two-Year Benefits in Achondroplasia

Price at Filing: $229.01

Real-time Price: $263.52

Change: +$34.50 (+15%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Mar 05, 2026, 5:04 PM EST

Filing Type: 144

Importance Score:

CEO Files Intent to Sell $22.7M in Shares from Expiring Warrants

Price at Filing: $237.29

Real-time Price: $263.52

Change: +$26.22 (+11%)

Market Cap: $16.437B

Sentiment: Negative

View Wiseek Article

ASND

Mar 02, 2026, 6:05 AM EST

Filing Type: 6-K

Importance Score:

FDA Approves Ascendis Pharma's YUVIWEL for Achondroplasia, Granting Priority Review Voucher

Price at Filing: $241.00

Real-time Price: $263.52

Change: +$22.51 (+9%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Feb 27, 2026, 6:01 PM EST

Source: Reuters

Importance Score:

U.S. FDA Approves Ascendis Pharma's Once-Weekly Therapy for Pediatric Dwarfism

Price at Filing: $233.50

Real-time Price: $263.52

Change: +$30.01 (+13%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Feb 23, 2026, 4:05 PM EST

Filing Type: 6-K

Importance Score:

Ascendis Pharma Proposes New Substantial Share Repurchase Authorization at AGM

Price at Filing: $234.95

Real-time Price: $263.52

Change: +$28.56 (+12%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Feb 11, 2026, 4:50 PM EST

Filing Type: 6-K

Importance Score:

Ascendis Pharma Reports Strong 2025 Financials, Positive Operating Cash Flow, and Advances Key Pipeline Programs

Price at Filing: $221.00

Real-time Price: $263.52

Change: +$42.51 (+19%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Feb 11, 2026, 4:15 PM EST

Filing Type: 20-F

Importance Score:

Ascendis Pharma Reports Strong 2025 Financials, Driven by YORVIPATH Sales & Pipeline Progress; Announces $120M Share Repurchase

Price at Filing: $216.23

Real-time Price: $263.52

Change: +$47.28 (+22%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Jan 12, 2026, 6:04 AM EST

Filing Type: 6-K

Importance Score:

Ascendis Pharma Unveils Strong Pipeline Progress & $120M Share Repurchase

Price at Filing: $207.00

Real-time Price: $263.52

Change: +$56.51 (+27%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

ASND

Jan 08, 2026, 6:26 PM EST

Filing Type: 6-K

Importance Score:

Ascendis Pharma Reports Strong Phase 2 Results for Achondroplasia Combination Therapy

Price at Filing: $208.75

Real-time Price: $263.52

Change: +$54.76 (+26%)

Market Cap: $16.437B

Sentiment: Positive

View Wiseek Article

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets

corporate_fare Company Profile